Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Weight Loss · GIP/GLP-1
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist with a 5-day half-life, demonstrating greater weight loss than semaglutide in head-to-head trials. Sold as Mounjaro (T2D) and Zepbound (obesity); widely compounded.
Tirzepatide is a dual GIP and GLP-1 receptor agonist with a 5-day half-life, demonstrating greater weight loss than semaglutide in head-to-head trials. Sold as Mounjaro (T2D) and Zepbound (obesity); widely compounded. Mechanism: GIP / GLP-1 dual agonist. Typical route: Subcutaneous injection. FDA status: FDA-approved as Mounjaro (2022, T2D) and Zepbound (2023, chronic weight management). Compounded tirzepatide is dispensed under the same FDA compounding framework as semaglutide and is subject to the A
Drug classGIP / GLP-1 dual agonist
Half-life~5 days (weekly dosing)
RouteSubcutaneous injection
Typical maintenance10-15 mg/week
FDA statusApproved (Mounjaro, Zepbound)
Compounded availabilityYes (503A/503B)
Mechanism of action
Tirzepatide simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. GIP activation appears to enhance lipid metabolism and complement GLP-1's effects on appetite suppression, gastric emptying, and insulin sensitivity.
Dosing reference
Standard titration: 2.5 mg/week (weeks 1-4), 5 mg/week (weeks 5-8), 7.5 mg/week (weeks 9-12), 10 mg/week (weeks 13-16), with optional escalation to 12.5 or 15 mg/week. Maintenance is typically 10-15 mg/week. Compounded versions commonly use 10, 20, or 40 mg/mL.
Dosing information is provided for educational reference and is not medical advice. Patients must not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
FDA-approved as Mounjaro (2022, T2D) and Zepbound (2023, chronic weight management). Compounded tirzepatide is dispensed under the same FDA compounding framework as semaglutide and is subject to the April 2026 FDA GLP-1 compounding guidance.
Editor's Pick · #1 of 10
NexLife — Semaglutide Program
Editor's PickPhysician-led503A pharmacyAll 50 states
Physician-led telehealth platform with Dr. Adam Kennah as Medical Director. Compounded semaglutide from an FDA-registered 503A pharmacy, all-inclusive pricing covering medication, supplies, and prescriber visits.
Trade-offs to know: Compounded medication, not FDA-approved Wegovy or Ozempic. Cash-pay only — not billable to insurance. Async telehealth model (no live video by default).
Editor's Pick · #1 of 10
NexLife — Tirzepatide Program
Editor's PickPhysician-led503A pharmacyAll 50 states
Physician-led tirzepatide program with the same compounding pharmacy, prescriber team, and clinical protocols as the semaglutide program. Methylcobalamin combined formulations available.
Trade-offs to know: Compounded medication, not FDA-approved Zepbound or Mounjaro. Cash-pay only. Tirzepatide is a newer compound with a shorter real-world safety record than semaglutide.
U.S. telehealth providers that work with Tirzepatide
Tirzepatide activates both the GIP and GLP-1 receptors, while semaglutide is a GLP-1-only agonist. In the SURMOUNT-1 trial, tirzepatide produced 20.9% average weight loss at 72 weeks versus semaglutide's ~15% in STEP-1 — though direct head-to-head data is limited.
Is compounded tirzepatide safe?
Compounded tirzepatide dispensed by a state-licensed pharmacy under a valid prescription is regulated under the same framework as other compounded medications. Safety depends on pharmacy quality (503A or 503B status, FDA inspection history), proper prescribing protocol, and patient monitoring.
Who is the Editor's Pick for compounded tirzepatide?
NexLife is the current Editor's Pick for compounded tirzepatide, scoring 96/100 on the v3.0 rubric. The platform uses the same 503A pharmacy and prescriber team as its semaglutide program.
SS
Lead Medical Researcher
Dr. Sam Saberian
Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.
AS
Medical Reviewer
Alen A. Schwartz, MD
Board-certified physician; reviews clinical accuracy of every published page.
JE
Edited by
Julliana Edwards
Editorial standards, factual accuracy, and corrections workflow.
Clinical evidence and access data
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
Evidence point
Published data
What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1
Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.
Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1
Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.
Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status
FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
Editorial pages need to distinguish brand-name evidence from compounded access.
State access
Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.
Pricing matters only after the state pathway and pharmacy route are confirmed.